Skip to main content
. Author manuscript; available in PMC: 2022 May 16.
Published in final edited form as: Cancer Res Commun. 2021 Nov;1(2):65–78. doi: 10.1158/2767-9764.CRC-21-0073

Figure 1. NURR1 confers to PDA chemoresistance.

Figure 1

A) The Cancer Genome Atlas (TCGA) research network for PDA database was used for expression of NURR1 mRNA and correlated with patient’s disease-free survival by using Kaplan– Meier survival analysis with log-rank tests P<0.016, B) NURR1 mRNA expression levels in PDA patients based on nodal metastasis status. For each boxplot, median expression value, and 1st and 3rd quartiles are indicated, **** p < 0.00001, C) NURR1 mRNA expression levels in PDA patients based on tumor grade, D) Immunoblot analysis of NURR1 protein lysates from MiaPaCa2 and Panc1 cells after 48 h of treatment with GEM (1μM), β-Tubulin serves as a loading control (3 independent experiments performed), E) Immunofluorescence staining of MiaPaCa2 and Panc1cells after 24 h of treatment with GEM (1μM) NURR1, Alexa Fluor 488 (green); nucleus, DAPI. Merged image, nuclear localization of NURR1 (3 independent experiments performed, and at least 10 images per slide were analyzed for each condition). Magnification 40x. F. Bars represent the quantification of mean intensity of NURR1 in the nucleus. Each data point represents the mean ± SEM of three independent experiments (*** p < 0.001).